BRAFV600E-Mutant Metastatic NSCLC: Disease Overview and Treatment Landscape

Authors

David Planchard
Rachel E Sanborn
Marcelo V Negrao
Aria Vaishnavi
Egbert F Smit

Publication Date

4-16-2024

Journal

NPJ Precision Oncology

Abstract

In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and emerging treatment options, BRAF sequencing approaches, and unmet needs. The BRAFV600E mutation confers constitutive activity of the MAPK pathway, leading to enhanced growth, proliferation, and survival of tumor cells. Testing for BRAF mutations enables patients to be treated with therapies that directly target BRAFV600E and the MAPK pathway, but BRAF testing lags behind other oncogene testing in metastatic NSCLC. Additional therapies targeting BRAFV600E mutations provide options for patients with metastatic NSCLC. Emerging therapies and combinations under investigation could potentially overcome issues of resistance and target non-V600E mutations. Therefore, because targeted therapies with enhanced efficacy are on the horizon, being able to identify BRAF mutations in metastatic NSCLC may become even more important.

Keywords

Non-small-cell lung cancer, Targeted therapies

Comments

This article has been corrected. See NPJ Precis Oncol. 2024 Jul 15;8:142.

Associated Data

PMID: 38627602